

## **Flex Pharma Scientific Advisory Board Co-Chairs Host Inaugural Summit on Muscle Cramps and Spasms with International Clinical and Scientific Experts**

[Click to Tweet this News](#)

Boston, MA (September 30, 2015) – Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, and its scientific co-founders, National Academy Sciences members Bruce Bean, Ph.D. of Harvard Medical School and Nobel laureate Rod MacKinnon, M.D. of the Rockefeller Institute, are hosting an inaugural summit of internationally renowned clinical experts and research thought leaders in the field of muscle cramps and spasms in Boston today. The purpose of this scientific conference is to discuss advances and potential treatments for muscle cramps by sharing the latest research amongst top colleagues in the field of neuromuscular physiology.

Dr. Rod MacKinnon noted, “This is a unique opportunity to gather the world’s leading clinical and scientific experts and thought leaders in field of muscle cramping to discuss how the discovery of stimulating particular nerves by transient receptor potential (TRP) channel activation has opened a potentially important, novel means of topical chemical neurostimulation which will potentially change the treatment paradigm for cramps and spasms.”

Attendees include:

1. **Bill David**, MD, PhD, Massachusetts General Hospital
2. **John Winkelman**, MD, PhD, Massachusetts General Hospital
3. **Rob Rosenberg**, MD, Physical Medicine & Rehabilitation Specialist
4. **Hal Pikus**, MD, Neurosurgeon
5. **CJ Heckman**, PHD, Northwestern University
6. **Chris Thompson**, PhD, Northwestern University
7. **Michael Johnson**, PhD, Northwestern University
8. **Christine Thomas**, PhD, University of Miami
9. **Brian Davis**, PhD, University of Pittsburgh
10. **Alan Light**, PhD, University of Utah
11. **Jie (Jeff) Zhang**, PhD, University of Utah
12. **Scott Garrison**, MD, PhD, University of Alberta
13. **Hans Katzberg**, MD, University of Toronto
14. **Rob Brownstone**, MD, PhD, University College London
15. **Marco Minetto**, MD, PhD, University of Turin

## **About Flex Pharma**

Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions. In three randomized, blinded, placebo-controlled, cross-over studies, Flex Pharma's proprietary treatment has shown a statistically significant reduction in the intensity of muscle cramps in healthy normal volunteers.

Flex Pharma was founded by National Academy of Sciences members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.

Individuals can follow the Company on Twitter (@flexpharma) and the Company's website (<http://ir.flex-pharma.com/>) to see the latest progress of the Company's pre-launch activities for its consumer product to prevent and treat exercise-associated muscle cramps.

## **Forward-Looking Statements**

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our plans to develop and commercialize our consumer products and the future availability of our consumer products. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation: the status, timing, costs, results and interpretation of our clinical studies; our ability to develop and commercialize our consumer products; anticipated positioning and product attributes of our consumer products; results of early clinical studies as indicative of the results of future trials; and other factors discussed in greater detail under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2014 and subsequent filings with the Securities and Exchange Commission (SEC). You are encouraged to read our filings with the SEC, available at [www.sec.gov](http://www.sec.gov), for a discussion of these and other risks and uncertainties. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

###

Contact:

Elizabeth Woo

SVP, Investor Relations & Corporate Communications

Flex Pharma, Inc.

[irdept@flex-pharma.com](mailto:irdept@flex-pharma.com)

617-874-1829